敌意
发表于 2025-3-25 05:30:21
http://reply.papertrans.cn/43/4214/421362/421362_21.png
FID
发表于 2025-3-25 10:46:10
http://reply.papertrans.cn/43/4214/421362/421362_22.png
持续
发表于 2025-3-25 14:41:47
http://reply.papertrans.cn/43/4214/421362/421362_23.png
Ostrich
发表于 2025-3-25 17:29:40
http://reply.papertrans.cn/43/4214/421362/421362_24.png
Peculate
发表于 2025-3-25 23:16:11
https://doi.org/10.1007/978-3-658-22663-3idemiological studies of 4–6% and a 12-month prevalence of 1.5–2% (Figure 2.1). Prevalence estimates inevitably vary depending on the strictness of the diagnostic definition used to define a case. Higher estimates can be expected if the less demanding one-month minimum duration criterion is applied.
BOOST
发表于 2025-3-26 00:17:15
https://doi.org/10.1007/978-3-476-03741-1found that comorbidity for any depressive or anxiety disorder was 91.3% (Figure 4.1).. This high level of comorbidity is similar to the estimate from the prospective naturalistic follow-up study of patients with anxiety disorders from the Harvard Brown Anxiety Disorders Research Program (HARP) where
无法治愈
发表于 2025-3-26 07:40:05
http://reply.papertrans.cn/43/4214/421362/421362_27.png
机构
发表于 2025-3-26 08:50:50
http://reply.papertrans.cn/43/4214/421362/421362_28.png
难取悦
发表于 2025-3-26 16:39:20
http://reply.papertrans.cn/43/4214/421362/421362_29.png
伸展
发表于 2025-3-26 16:54:57
https://doi.org/10.1007/978-3-662-63641-1choices either for GAD as a whole or for selective treatments for particular subgroups of GAD. The best guidance therefore comes from a careful analysis of the data from placebo-controlled studies that indicate the strengths and weaknesses of particular treatments.